ARTICLE | Clinical News
IPX159: Phase IIb started
January 2, 2012 8:00 AM UTC
Impax began a double-blind, placebo-controlled, North American Phase IIb trial evaluating oral IPX159 in about 120 patients with moderate to severe RLS for up to 11 weeks. ...